Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, May 26, 2016

FTY720 Preserves Blood-Brain Barrier Integrity Following Subarachnoid Hemorrhage in Rats

Would this be a possible solution to  Inflammatory action leaking through the blood brain barrier. in the neuronal cascade of death? More research needed that will never occur.
  1. Fernando Testai2,3
  1. Neurology vol. 86 no. 16 Supplement P5.230

Abstract

Objective: In this study we investigated the effect of FTY720 in BBB function in the rat model of SAH.  
Background: In a recent study we showed that the sphingosine-1-phosphate agonist FTY720 reduces neuroinflammation, preserves pial arteriolar reactivity, and improves neurological outcome in rats subjected to subarachnoid hemorrhage (SAH). The immune response triggered by SAH leads to blood-brain barrier (BBB) disruption and brain edema formation which are important determinants of outcome.  
Methods: SAH was induced in rats via endovascular perforation of the anterior cerebral artery. Animals were divided into three groups: (1) sham control; (2) SAH-vehicle; (3) SAH-FTY720 treated. FTY720 (0.5 mg/kg) was applied intraperitoneally 3h post SAH. Brain tissue was collected 48h post SAH. BBB integrity was evaluated based on parenchymal extravasation of Evan’s blue (EB) and the expression of endothelial barrier antigen (EBA) and tight junction proteins (ZO-1 and occludin). Brain edema was assessed by measuring the brain water content using the weight/dry method.  
Results: The parenchymal extravasation of EB in the SAH-vehicle group was significantly higher than in the sham group (12.96±3.14 µg/g tissue, vs. 3.20±2.12 µg/g tissue in the sham surgical group; p<0.01). The treatment with FTY720 reduced the extravasation of EB by almost 50[percnt] (6.96±2.83 µg/g tissue). Immunohistochemistry staining demonstrated that ZO-1 and occludin, along with cerebral microvessels (EBA), held a strong perivascular expression pattern in the sham-control group. At 48h post SAH, the expression of these markers was reduced in the SAH-vehicle group but largely preserved in the SAH rats treated with FTY720. Also, the brain water content was significantly increased after SAH (SAH: 82.50±0.94[percnt], vs. sham: 79.38±0.37[percnt]; p<0.01), but this was normalized by the treatment with FTY720 (79.63±0.72 [percnt]). Conclusions: These results suggest that the neuroprotective role of FTY720 extends to the preservation of BBB integrity and attenuation of cerebral edema following SAH.

No comments:

Post a Comment